Description
This reports analytics model will help you compete in The Market for Cell-Based Assays:
- Estimate market size, share and growth by region, industry segment and product category
- Understand the drivers of brand loyalty and compare brand performance
- Measure customer satisfaction with instrumentation and consumables
- Highlight the strengths and weaknesses of competitors and their customers’ likelihood-to-switch
- Compare to 2015 data to monitor trends and identify changes
Overview
Cell-based assays have become an essential tool for both academic and industry-based research for a wide variety of applications. These assays allow scientists to analyze complex cellular functions; to probe the relationship between cellular dysfunction and disease; to enable pathway-specific drug screening; and to study the effects of adding, deleting, or mutating single proteins. Cell-based assays give researchers the ability to study intact pathways as well as the interaction between different pathways – providing richer data than can be derived from biochemical assays composed of purified cellular components. In addition, cell-based assays deliver higher throughput capability when compared with in vivo studies.
The 2016 Market for Cell-Based assays helps suppliers of instrumentation and consumables track important trends in this constantly evolving market. Many scientists are increasingly working to improve the biological relevance of their assays to more effectively simulate human in vivo conditions. Others, especially those engaged in drug discovery employ phenotypic assays to measure functional responses of cells to stimuli along with the effects of drug candidates on those responses. These trends are driving demand for cell lines that express functional proteins of interest, for primary cells that exhibit native activities, for assays with convenient and robust readouts, and for 3-D cell culture models that mimic complex tissue structure. ATCC, BD Biosciences, Bio-Rad, CST, Corning, Lonza, Millipore Sigma, and Thermo Fisher – along with many others – compete in the market for cells, kits and consumables.
The microplate reader remains the critical instrumentation platform of the cell-based assay market. Life science suppliers have responded to the market’s demand for flexibility with both single detection and multi-mode microplate readers to accommodate the diversity of cell-based assays. New platforms accommodate a full range of detection technologies into a single instrument, greatly enhancing convenience and lowering costs to the end user who would have previously been forced to purchase multiple instruments to accommodate multiple readouts. Berthold BioTek, Instruments, BMG Labtech Molecular Devices, Perkin Elmer, Promega, Tecan, and Thermo Fisher are all major players in the microplate market. Label-free detection is of increasing importance to conduct pathway analysis (SPR instrumentation from GE Healthcare Life Sciences and Bio-Rad Laboratories) and to measure metabolic cell health (Agilent’s Seahorse Bioscience XF analyzers).
